MDGL R&D to Revenue
Madrigal Pharmaceuticals Inc · R&D to Revenue
MDGL R&D to Revenue
Latest reported25.03%period ending
MDGL Quarterly R&D/Revenue (3251.45% → 25.03%)
Latest values, visible window
High-resolution chart · PNG
MDGL r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 25.0316% | |
| 34.9114% | |
| 36.2112% | |
| 60.572% | |
| 25.4138% | |
| 32.1836% | |
| 24.8238% | |
| 110.5621% | |
| 485.6606% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 192.9676% | |
| 0% | |
| 0% | |
| 8,208.1633% | |
| 317.2363% | |
| 646.0938% | |
| 769.3501% | |
| 825.5468% | |
| 231.5085% | |
| 325.8351% | |
| 288.3333% | |
| 253.4178% | |
| 197.2863% | |
| 6.966% | |
| 217.1613% | |
| 501.9734% | |
| 3,621.2264% | |
| 1,891.3522% | |
| 1,370.852% | |
| 1,207.0254% | |
| 1,794.6164% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 3,251.4451% |